Structure-activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V

Antiviral Therapy

Volumn 15, Issue 6, 2010, Pages 841-852

  Örtqvist, Pernilla ^a   Vema, Aparna ^a   Ehrenberg, Angelica E ^a   Dahl, Göran ^a   Rönn, Robert ^a   Åkerblom, Eva ^a   Karlén, Anders ^a   Danielson, U Helena ^a   Sandström, Anja ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; CILUPREVIR; ITMN 191; NONSTRUCTURAL PROTEIN 3; NORVALINE; PHENYLGLYCINE; PROLINE; PROTEINASE INHIBITOR; TELAPREVIR;

ARTICLE; DRUG ACTIVITY; DRUG BINDING; DRUG POTENCY; DRUG SENSITIVITY; ENZYME INHIBITION; HEPATITIS C VIRUS; MOLECULAR MODEL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

DRUG RESISTANCE, VIRAL; HEPACIVIRUS; MODELS, MOLECULAR; PROTEASE INHIBITORS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 77957366855     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1655     Document Type: Article

References (35)

1. Shepard CW, Finelli L, Alter M. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567. (Pubitemid 41196755)
2. Webster DP, Klenerman P, Collier J, Jeffery KJM. Development of novel treatments for hepatitis C. Lancet Infect Dis 2009; 9:108-117.
3. Zeuzem S, Schmidt JM, Lee J-H, Von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28:245-252. (Pubitemid 28300008)
4. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107. (Pubitemid 28471138)
5. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A 1991; 88:3392-3396. (Pubitemid 21916627)
6. Okamoto H, Kojima M, Okada SI, et al. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 1992; 190:894-899.
7. White PW, Llinas-Brunet M, Bos M. Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease. Prog Med Chem 2006; 44:65-107. (Pubitemid 43668369)
8. Trail watch: protease inhibitors show promise against HCV. Nat Rev Drug Discov 2009; 8:11.
9. Lu L, Pilot-Matias TJ, Stewart KD, et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 2004; 48:2260-2266. (Pubitemid 38691627)
10. Lin C, Lin K, Luong Y-P, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279:17508-17514.
11. He Y, King MS, Kempf DJ, et al. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother 2008; 52:1101-1110. (Pubitemid 351358394)
12. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132:1767-1777.
13. Qiu P, Sanfiorenzo V, Curry S, et al. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res 2009; 37:e74.
14. Cubero M, Esteban JI, Otero T, et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 2008; 370:237-245.
15. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198:800-807.
16. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48:1769-1778.
17. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009; 49:1069-1082.
18. Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005; 280:36784-36791.
19. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006; 70:28-38.
20. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967; 27:157-162.
21. Trozzi C, Bartholomew L, Ceccacci A, et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 2003; 77:3669-3679.
22. Courcambeck J, Bouzidi M, Perbost R, et al. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Antivir Ther 2006; 11:847-855.
23. Dahl G, Sandström A, Åkerblom E, Danielson UH. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3. Antivir Ther 2007; 12:733-740.
24. Rönn R, Sabnis YA, Gossas T, et al. Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3. Bioorg Med Chem 2006; 14:544-559.
25. Rönn R, Gossas T, Sabnis YA, et al. Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors. Bioorg Med Chem 2007; 15:4057-4068.
26. Rönn R, Lampa A, Peterson SD, et al. Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety. Bioorg Med Chem 2008; 16:2955-2967.
27. Örtqvist P, Peterson SD, Åkerblom E, et al. Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors. Bioorg Med Chem 2007; 15:1448-1474.
28. Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 1999; 7:1353-1363.
29. Still WC, Tempczyk A, Hawley RC, Hendrickson T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J Am Chem Soc 1990; 112:6127-6129.
30. McMartin C, Bohacek RS. QXP: powerful, rapid computer algorithms for structure-based drug design. J Comput Aided Mol Des 1997; 11:333-344.
31. Kolossvary I, Guida WC. Low Mode Search. An efficient, automated computational method for conformational analysis: application to cyclic and acyclic alkanes and cyclic peptides. J Am Chem Soc 1996; 118:5011-5019.
32. Kolossvary I, Guida WC. Low-mode conformational search elucidated: application to C39H80 and flexible docking of 9-deazaguanine inhibitors into PNP. J Comput Chem 1999; 20:1671-1684.
33. Chang G, Guida WC, Still WC. An internal-coordinate Monte Carlo method for searching conformational space. J Am Chem Soc 1989; 111:4379-4386.
34. Gulnik SV, Suvorov LI, Liu B, et al. kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995; 34:9282-9287.
35. McGaughey GB, Gagne M, Rappe AK. π-Stacking interactions - alive and well in proteins. J Biol Chem 1998; 273:15458-15463.